New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
about
Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic painDiverse mechanisms of antiepileptic drugs in the development pipelineCould valerian have been the first anticonvulsant?Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in miceDivalproex sodium in the treatment of pediatric psychiatric disorders.New antiepileptic drugs that are second generation to existing antiepileptic drugs.Valproic Acid: second generation.Anticonvulsant efficacy of valproate-like carboxylic acids: a potential target for anti-bipolar therapy.Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.Valproic acid protects against haemorrhagic shock-induced signalling changes via PPARγ activation in an in vitro modelValproic Acid Enhances iPSC Induction From Human Bone Marrow-Derived Cells Through the Suppression of Reprogramming-Induced Senescence.The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid.Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.The activity of antiepileptic drugs as histone deacetylase inhibitors.Valproic acid extends Caenorhabditis elegans lifespan.Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder.Molecular approaches to developmental malformations using analogous forms of valproic acid.QSPR Study of Valproic Acid and Its Functionalized Derivatives.
P2860
Q24670430-54EB30BB-90FB-4E97-B258-01841D951464Q24675330-24297F5B-A216-4030-A945-35E98D5E7E9DQ28290116-1416EC11-6C20-4BFD-82B0-EF874CD6F38FQ35045414-B2A537E8-59AC-417F-80E2-379084D13BACQ36106793-47BAE1A0-6B85-43EC-B61C-A4712D008669Q36491829-9B5DF78A-2B8C-4582-BFA1-9141E6945599Q36697494-DBDFB2E0-4E46-487A-9983-976644B25C1DQ36789953-B89809BD-00CD-4F56-A768-AE9F1609F1EBQ37114055-3F62A82C-95A4-496E-B74C-99DCA4BDFC2DQ37441534-1915DA2C-642C-47DD-9F88-6FB096C7A38BQ38815636-53AD92A9-C8AF-47FB-BA0A-7AF32F807E65Q39608766-8B185DF2-FA7C-47AC-AEFB-D3AB7534FB7DQ40039773-5BEBFF51-81F7-457C-BB60-3A3A0A12962AQ44961269-92F06964-1A3A-416F-8E10-0C72FE3D2C0BQ46772888-0BB5715C-888E-4D1D-BF68-969681FE2CB7Q51822772-EACD1284-7B65-4ED4-BBC1-C68667295F1EQ52016604-E43CB560-D984-4FC9-9378-E6045E02AA45Q53767428-926557B5-50D3-41E1-8621-FF19367C7805
P2860
New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
New CNS-active drugs which are ...... development of a magic bullet?
@ast
New CNS-active drugs which are ...... development of a magic bullet?
@en
type
label
New CNS-active drugs which are ...... development of a magic bullet?
@ast
New CNS-active drugs which are ...... development of a magic bullet?
@en
prefLabel
New CNS-active drugs which are ...... development of a magic bullet?
@ast
New CNS-active drugs which are ...... development of a magic bullet?
@en
P2093
P1476
New CNS-active drugs which are ...... development of a magic bullet?
@en
P2093
Boris Yagen
Meir Bialer
Nina Isoherranen
P304
P356
10.1097/00019052-200304000-00014
P577
2003-04-01T00:00:00Z